Products

What will AGI do for Anistreplase?

This classification denotes an acylated inactive complex of streptokinase and human lysine-plasminogen; after injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5O8V541HJ6. European Medicines Agency schedules Anistreplase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00538MIG. The term ANISTREPLASE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29.) Most nations schedule Anistreplase under HS 35079090 and SITC 51691. SMILES:. As of Q4 2014, ANISTREPLASE remains the US FDA Preferred Term for this commodity. .

How AGI delivers it

Four ways AGI delivers for Anistreplase

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Anistreplase, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Anistreplase, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Anistreplase connects

measured by

  • Deacylation Ratemodel
  • Enzyme Specific Activitymodel
  • Fibrinolytic Activitymodel
  • Microbial Sterilitymodel
  • Protein Contentmodel